• Original article (Basic research) • Previous Articles     Next Articles

Effects of histone deacetylase 6 on α-synuclein-positive inclusion bodies in the cell model of Parkinson's disease

WANG Fei1,2, DU Yun-lan2, LI Yan-sheng1,2   

  1. 1.Department of Neurology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai 201112, China; 2.Department of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
  • Online:2015-12-28 Published:2016-01-21
  • Supported by:

    Young Scientists Project of National Natural Science Foundation of China， 81000538

PDF (PC)

872

Abstract:

Objective  To investigate the expression of histone deacetylase 6 (HDAC6) and its effects on α-synuclein-positive inclusion bodies in the cell model of Parkinson's disease (PD). Methods  The human neuroblastoma cells SK-N-SH with stable over-expressed wild type α-synuclein were constructed via Lipofectamin 2000. The PD model with abnormal aggregation of α-synuclein was established by adding the proteasome inhibitor lactacystin. The expression of HDAC6 was detected by Western blotting. After being treated with HDAC6 specific inhibitor tubacin, the level of α-synuclein-positive inclusion bodies was detected by immunofluorescence staining. Results  Compared with the controls, the expression of HDAC6 of lactacystin-treated cells was significant higher and α-synuclein-positive inclusion bodies were more. Treatment by tubacin reduced the amount of inclusion bodies and the difference was statistically significant (P＜0.05). Conclusion  In the PD cell model established by proteasome inhibitor, inhibition of increased HDAC6 can reduce the amount of α-synuclein-positive inclusion bodies, which may be relevant to the involvement of HDAC6 in the conversion of α-synuclein from oligomers to inclusion bodies, so as to play a role of protection.

Key words: Parkinson's disease, histone deacetylase 6, α-synuclein, inclusion body